Clinical Trials
Espansione's evidence base is built on clinical studies rather than testimonial. This page summarises the principal completed trials and the ongoing research programme, across both the front and the back of the eye.
Dry eye and MGD: randomised controlled trials
The foundation is a set of randomised controlled trials in meibomian gland dysfunction, which provide the head-to-head comparisons on which any comparative claim properly rests:
- LM™ LLLT versus OPE™ IPL: LM™ LLLT improved symptom scores and tear meniscus height more than IPL at two-week follow-up (Giannaccare et al., 2022, Cornea).
- Combined therapy versus IPL-only comparator: combined OPE™ IPL plus LM™ LLLT was superior at eighteen-month follow-up (Leite et al., 2025).
- Combined therapy versus competitor IPL-only devices: superior on lipid layer thickness and symptoms (Castro et al., 2023).
- Combined therapy versus eye drops: superior to sodium hyaluronate on tear breakup time and symptoms (Meduri et al., 2022).
See combined therapy for how these fit together.
Dry AMD: from pilot to multicentric trial
In the posterior segment, early studies established safety and short-term signals in intermediate dry AMD. Borrelli et al. (2024, Ophthalmology and Therapy) reported on the safety, tolerability and short-term efficacy of eye-light® photobiomodulation, and Viggiano et al. (2025, Eye) documented choriocapillaris perfusion enhancement and outer retinal remodelling, with visual acuity improvement and drusen volume reduction at follow-up, following a regimen of eight sessions over four weeks.
Building on these pilot studies, the DRUSEN trial, a 12-month, multicentre, randomised, double-masked, sham-controlled investigation across six European centres, has now reported its results (Iovino et al., 2026, British Journal of Ophthalmology). In 138 eyes with early and intermediate dAMD, PBM on eye-light® significantly reduced mean drusen volume and improved best-corrected visual acuity relative to sham, a between-group difference of 3.75 ETDRS letters (95% CI 1.16 to 6.34). Four eyes in the sham group progressed to neovascular (wet) AMD compared with none in the PBM group, and no retinal phototoxicity was observed. Treatment used two wavelengths, yellow (around 590 nm) and red (around 625 nm), delivered over two cycles. Longer follow-up is still needed to confirm any effect on long-term disease progression.
Surgical and perioperative care
Randomised, sham-controlled trials now support light-based therapy around eye surgery. Perioperative LM™ LLLT preserved tear volume (tear meniscus height and Schirmer values) and patient comfort after Femto-LASIK, where the sham group declined significantly over three months; tear-film stability measures did not differ significantly between groups (Solarino et al., 2026, Therapeutic Advances in Ophthalmology). Comparable benefit has been reported around cataract surgery (Giannaccare et al., 2024, British Journal of Ophthalmology). See surgical applications.
How to read the evidence
The dry eye and MGD evidence is the most mature, anchored in randomised controlled trials and reflected in TFOS DEWS III. The AMD evidence is now anchored by a 12-month randomised controlled trial, with longer follow-up still to come, and the perioperative evidence rests on sham-controlled trials. Throughout, comparative claims are confined to head-to-head data, and cleared indications vary by region.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.